Navigation Links
RTOG activates study to determine best treatment strategies for patients with glioma brain tumors
Date:12/15/2011

Treatment remains controversial for patients diagnosed with a low-risk, low-grade glioma (LGG) brain tumor. These patients have significantly better prognosis than patients diagnosed with more aggressive high-grade glioma, and their clinical care often involves ongoing observation for tumor changes with imaging studies. Because low-risk LGG are slow growing tumors, concerns about the potential adverse effects of early treatment on patients' neurocognitive function (NCF) and quality of life (QOL) may outweigh treatment benefits in patients who are frequently young and highly functional.

Although a low-grade tumor, LGG has a significant potential for transforming into a high-grade glioma. "Currently there is no consensus on when and how best to treat this tumor," says RTOG 0925 principal investigator Ali K. Choucair, M.D., Director of Neuro-oncology and Co-director of the Brain Tumor Center at the Neuroscience Institute, Norton Healthcare System, Louisville, KY. "The RTOG 0925 study was designed with compilation of best available data from both prospective as well as retrospective studies in an effort to identify early clinical and neurocognitive changes that could precede changes observed on imaging scans and could trigger early and timely treatment," Choucair explains.

The study's goal is to better understand the affects of tumor progression on patients with low-risk LGG. The phase II trial will enroll 170 study participants with newly diagnosed LGG who are undergoing observation alone for clinical care. The study will compare NCF, QOL, and seizure control over time in patients who have evidence of tumor progression versus patients who have no evidence of progression as determined by magnetic imaging resonance (MRI) scans. "Standardized and clinically meaningful definitions of tumor progression in low-risk LGG are clearly needed to further the examination and understanding of these tumors," says Walter J. Curran, Jr., MD, RTOG Group Chair, and Executive Director of the Winship Cancer Institute of Emory University in Atlanta, "It is hoped the study's findings will help guide future treatment decisions for these patients," Curran concludes.

The study also has an important translational research component that is expected to contribute much needed information to current limited knowledge about the role molecular markers in predicting LGG tumor progression. Tumor tissue from consenting study participants will be used to evaluate molecular correlates of NCF, QOL, seizure control, and progression-free survival. Such information has the potential to aid clinical decision-making and further the identification of individualized patient therapy approaches.

Patients who have disease progression while enrolled on RTOG 0925 may be eligible for entry on a trial available to RTOG members through the NCI Clinical Trials Support Unit (CTSU) sponsored by ECOG, E3F05/RTOG 1072, Phase III Randomized Study of Radiotherapy With Versus Without Temozolomide in Patients With Symptomatic or Progressive Low-Grade Gliomas.


'/>"/>
Contact: Nancy Fredericks
nfredericks@acr.org
215-717-2769
American College of Radiology
Source:Eurekalert

Related medicine news :

1. Molecule Nutlin-3a activates a signal inducing cell death and senescence in primary brain tumors
2. Targeted therapy reactivates guardian of the genome in resistant cancer
3. Transcendental Meditation activates default mode network, the brains natural ground state
4. Arsenic exposure activates an oncogenic signaling pathway; leads to increased cancer risk
5. Heart failure study: Health-literate patients not always adept at managing care
6. Higher Hospital Admissions Equal Higher Readmissions: Study
7. Study takes aim at education-based death rate disparities
8. Study Finds Fewer Blood Transfusions Needed After Hip Surgeries
9. Wayne State study shows early research on cellphone conversations likely overestimated crash risk
10. Heart drug may be effective for managing certain cancers: Queens University study
11. Working Moms Happier, Healthier Than Stay-at-Home Peers: Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... ... , ... Florida Hospital presents Heart Health Awareness night on Sunday February 14th, ... Amalie Arena. The puck drops at 6:00pm, but fans will have the opportunity to ... the game. The MEGA Heart will be located on Ford Thunder Alley and provide ...
(Date:2/11/2016)... IL (PRWEB) , ... February 11, 2016 , ... ... to the healthcare industry, ranked among the top five firms in the “2015/2016 ... and HIT Implementation Support and Staffing. KLAS is a research and insights firm ...
(Date:2/11/2016)... ... ... In a new paper published in the latest issue ... Rohrich, and colleagues, examine and underscore the importance of upper lateral cartilage in ... this vital area. , The upper lateral cartilage in rhinoplasty, refers to a ...
(Date:2/11/2016)... ... February 11, 2016 , ... "What ... and author Ray Clarke poses a question as a challenge for his readers ... book, "Being in the Being" (published by Partridge Singapore), Clarke explores the subject ...
(Date:2/11/2016)... ... February 11, 2016 , ... Colorado spine surgeon, Donald Corenman, MD, ... spine surgeons to know in 2016 . The list consists of spine surgeons across ... , Dr. Corenman understands the importance of clinical excellence; he has been awarded ...
Breaking Medicine News(10 mins):
(Date:2/11/2016)... 11, 2016 F ast ... answers at the point ... of scientific, technical and medical information products and services, has launched a ... reviewed clinical information via a mobile device. Elsevier designed the mobile app ... The new app is available in Android and iOS ...
(Date:2/11/2016)... investment" by Bruce Montgomery , one of this area,s most prominent biotech executives, and his ... , PhD. Photo - http://photos.prnewswire.com/prnh/20160211/332242 ... ... ... Kawas said the round was intended to be an $8 million raise but ...
(Date:2/11/2016)...  AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX ) today ... the 38th annual John A. Boswick , ... being held February 14-18, 2016 in Hawaii ... in wound healing, burn care, and infection control, and ... Burns Association, Academy of Physicians in Wound Care and ...
Breaking Medicine Technology: